BiotechTube

NBI-98854

Phase 2Terminated
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tourette Syndrome

Conditions

Tourette Syndrome

Trial Timeline

Oct 17, 2018 → Feb 18, 2019

NCT ID
NCT03732534

About NBI-98854

NBI-98854 is a phase 2 stage product being developed by Neurocrine Biosciences for Tourette Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT03732534. Target conditions include Tourette Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (4)

NCT IDPhaseStatus
NCT03732534Phase 2Terminated
NCT02405091Phase 3Completed
NCT02256475Phase 1Completed
NCT01267188Phase 2Completed

Competing Products

12 competing products in Tourette Syndrome

See all competitors
ProductCompanyStageHype Score
AZD5213 and placeboAstraZenecaPhase 2
52
PF-03654746 + Placebo + Placebo + PF-03654746PfizerPhase 2
51
AripiprazoleBristol Myers SquibbPre-clinical
22
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 2
49
NBI-98854Neurocrine BiosciencesPhase 1
30
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
Abobotulinum toxin AIpsenPre-clinical
20
Tetrabenazine MR + PlaceboBausch HealthPhase 2
47

Other Products from Neurocrine Biosciences

Valbenazine Oral CapsuleApproved
82
ValbenazineApproved
82
ValbenazineApproved
82
Valbenazine + Placebo oral capsuleApproved
82
Valbenazine + Placebo oral capsuleApproved
82